Mapping the binding site topology of amyloid protein aggregates using multivalent ligands

A key process in the development of neurodegenerative diseases such as Alzheimer's and Parkinson's diseases is the aggregation of proteins to produce fibrillary aggregates with a cross beta-sheet structure, amyloid. The development of reagents that can bind these aggregates with high affinity and selectivity has potential for early disease diagnosis. By linking two benzothiazole aniline (BTA) head groups with different length polyethylene glycol (PEG) spacers, fluorescent probes that bind amyloid fibrils with low nanomolar affinity have been obtained. Dissociation constants measured for interaction with A beta, alpha-synuclein and tau fibrils show that the length of the linker determines binding affinity and selectivity. These compounds were successfully used to image alpha-synuclein aggregates in vitro and in the postmortem brain tissue of patients with Parkinson's disease. The results demonstrate that multivalent ligands offer a powerful approach to obtain high affinity, selective reagents to bind the fibrillary aggregates that form in neurodegenerative disease.

Automated summary

The development of reagents that can bind protein aggregates related to neurodegenerative diseases such as Alzheimer's and Parkinson's is crucial for early disease diagnosis. By linking two benzothiazole aniline head groups with different length polyethylene glycol spacers, fluorescent probes with high affinity for amyloid fibrils have been obtained. These compounds have shown promise in imaging neurodegenerative disease-related protein aggregates in vitro and in postmortem brain tissue.